XML 38 R27.htm IDEA: XBRL DOCUMENT
v3.25.3

REVISIONS TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Accounting Changes and Error Corrections [Abstract] |
SCHEDULE OF REVISION ON THE PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS | SCHEDULE OF REVISION ON THE PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
|  | As of and for the Year Ended December 31, 2024 |
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
Consolidated Balance Sheet: |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  | $ | 8,217,813 |  |  | $ | 2,636,271 |  |  | $ | 10,854,084 |
Other current assets |  | $ | 2,672,231 |  |  | $ | 1,000,000 |  |  | $ | 3,672,231 |
Total Current Assets |  | $ | 48,733,089 |  |  | $ | 3,636,271 |  |  | $ | 52,369,360 |
Total Assets |  | $ | 72,460,026 |  |  | $ | 3,636,271 |  |  | $ | 76,096,297 |
Accrued expenses |  | $ | 20,811,763 |  |  | $ | 2,000,000 |  |  | $ | 22,811,763 |
Deferred revenue |  | $ | 14,480,917 |  |  | $ | 5,145,023 |  |  | $ | 19,625,940 |
Total Current Liabilities |  | $ | 60,255,145 |  |  | $ | 7,145,023 |  |  | $ | 67,400,168 |
Total Liabilities |  | $ | 76,505,394 |  |  | $ | 7,145,023 |  |  | $ | 83,650,417 |
Accumulated deficit |  | $ | 236,253,218 |  |  | $ | 3,597,713 |  |  | $ | 239,850,931 |
Total LifeMD, Inc. Stockholders’ Deficit |  | $ | 5,485,501 |  |  | $ | 3,597,713 |  |  | $ | 9,083,214 |
Non-controlling interest |  | $ | (1,440,133 | ) |  | $ | (88,961 | ) |  | $ | (1,529,094 | )
Total Stockholders’ Deficit |  | $ | 4,045,368 |  |  | $ | 3,508,752 |  |  | $ | 7,554,120 |
Total Liabilities, Mezzanine Equity and Stockholder’s Deficit |  | $ | 72,460,026 |  |  | $ | 3,636,271 |  |  | $ | 76,096,297 |
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
Consolidated Statement of Operations: |  |  |  |  |  |  |  |  |  |  |  |
Telehealth revenue, net |  | $ | 158,438,631 |  |  | $ | (3,614,556 | ) |  | $ | 154,824,075 |
Total revenues, net |  | $ | 212,453,838 |  |  | $ | (3,614,556 | ) |  | $ | 208,839,282 |
Gross profit |  | $ | 188,385,359 |  |  | $ | (3,614,556 | ) |  | $ | 184,770,803 |
General and administrative expenses |  | $ | 72,662,021 |  |  | $ | (1,482,913 | ) |  | $ | 71,179,108 |
Total expenses |  | $ | 204,530,040 |  |  | $ | (1,482,913 | ) |  | $ | 203,047,127 |
Operating loss |  | $ | (16,144,681 | ) |  | $ | (2,131,643 | ) |  | $ | (18,276,324 | )
Loss from operations before income taxes |  | $ | (18,326,498 | ) |  | $ | (2,131,643 | ) |  | $ | (20,458,141 | )
Net loss |  | $ | (18,728,498 | ) |  | $ | (2,131,643 | ) |  | $ | (20,860,141 | )
Net income attributable to noncontrolling interests |  | $ | 153,234 |  |  | $ | 395,641 |  |  | $ | 548,875 |
Net loss attributable to LifeMD, Inc. |  | $ | (18,881,732 | ) |  | $ | (2,527,284 | ) |  | $ | (21,409,016 | )
Net loss attributable to LifeMD, Inc. common stockholders |  | $ | (21,987,982 | ) |  | $ | (2,527,284 | ) |  | $ | (24,515,266 | )
Basic loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.53 | ) |  | $ | (0.07 | ) |  | $ | (0.60 | )
Diluted loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.53 | ) |  | $ | (0.07 | ) |  | $ | (0.60 | )
Consolidated Statement of Changes in Stockholders’ Equity (Deficit): |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | 236,253,218 |  |  | $ | 3,597,713 |  |  | $ | 239,850,931 |
Non-controlling interest |  | $ | (1,440,133 | ) |  | $ | (88,961 | ) |  | $ | (1,529,094 | )
Consolidated Statement of Cash Flows: |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (18,728,498 | ) |  | $ | (2,131,643 | ) |  | $ | (20,860,141 | )
Accounts receivable |  | $ | (2,940,563 | ) |  | $ | (1,647,760 | ) |  | $ | (4,588,323 | )
Other current assets |  | $ | (1,737,721 | ) |  | $ | (1,000,000 | ) |  | $ | (2,737,721 | )
Deferred revenue |  | $ | 5,652,319 |  |  | $ | 4,262,316 |  |  | $ | 9,914,635 |
Accrued expenses |  | $ | 7,502,624 |  |  | $ | 517,087 |  |  | $ | 8,019,711 |
Net cash provided by operating activities |  | $ | 17,513,190 |  |  | $ | - |  |  | $ | 17,513,190 |
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
|  | For the Three Months Ended September 30, 2024 |
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
Condensed Consolidated Statement of Operations: |  |  |  |  |  |  |  |  |
Telehealth revenue, net |  | $ | 40,275,546 |  |  | $ | (120,863 | ) |  | $ | 40,154,683 |
Total revenues, net |  | $ | 53,393,157 |  |  | $ | (120,863 | ) |  | $ | 53,272,294 |
Gross profit |  | $ | 48,379,616 |  |  | $ | (120,863 | ) |  | $ | 48,258,753 |
General and administrative expenses |  | $ | 18,925,844 |  |  | $ | (810,701 | ) |  | $ | 18,115,143 |
Total expenses |  | $ | 53,065,728 |  |  | $ | (810,701 | ) |  | $ | 52,255,027 |
Operating loss |  | $ | (4,686,112 | ) |  | $ | 689,838 |  |  | $ | (3,996,274 | )
Loss from operations before income taxes |  | $ | (5,244,709 | ) |  | $ | 689,838 |  |  | $ | (4,554,871 | )
Net loss |  | $ | (5,477,232 | ) |  | $ | 689,838 |  |  | $ | (4,787,394 | )
Net loss attributable to non-controlling interests |  | $ | (345,767 | ) |  | $ | 216,295 |  |  | $ | (129,472 | )
Net loss attributable to LifeMD, Inc. |  | $ | (5,131,465 | ) |  | $ | 473,543 |  |  | $ | (4,657,922 | )
Net loss attributable to LifeMD, Inc. common stockholders |  | $ | (5,908,028 | ) |  | $ | 473,543 |  |  | $ | (5,434,485 | )
Basic loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.14 | ) |  | $ | 0.01 |  |  | $ | (0.13 | )
Diluted loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.14 | ) |  | $ | 0.01 |  |  | $ | (0.13 | )
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
|  | As of and for the Nine Months Ended September 30, 2024 |
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
Condensed Consolidated Statement of Operations: |  |  |  |  |  |  |  |  |
Telehealth revenue, net |  | $ | 108,549,257 |  |  | $ | 1,137,797 |  |  | $ | 109,687,054 |
Total revenues, net |  | $ | 148,199,266 |  |  | $ | 1,137,797 |  |  | $ | 149,337,063 |
Gross profit |  | $ | 133,560,633 |  |  | $ | 1,137,797 |  |  | $ | 134,698,430 |
General and administrative expenses |  | $ | 52,752,961 |  |  | $ | (1,592,078 | ) |  | $ | 51,160,883 |
Total expenses |  | $ | 150,723,556 |  |  | $ | (1,592,078 | ) |  | $ | 149,131,478 |
Operating loss |  | $ | (17,162,923 | ) |  | $ | 2,729,875 |  |  | $ | (14,433,048 | )
Loss from operations before income taxes |  | $ | (18,730,666 | ) |  | $ | 2,729,875 |  |  | $ | (16,000,791 | )
Net loss |  | $ | (18,963,189 | ) |  | $ | 2,729,875 |  |  | $ | (16,233,314 | )
Net (loss) income attributable to noncontrolling interests |  | $ | (187,729 | ) |  | $ | 424,766 |  |  | $ | 237,037 |
Net loss attributable to LifeMD, Inc. |  | $ | (18,775,460 | ) |  | $ | 2,305,109 |  |  | $ | (16,470,351 | )
Net loss attributable to LifeMD, Inc. common stockholders |  | $ | (21,105,148 | ) |  | $ | 2,305,109 |  |  | $ | (18,800,039 | )
Basic loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.52 | ) |  | $ | 0.06 |  |  | $ | (0.46 | )
Diluted loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.52 | ) |  | $ | 0.06 |  |  | $ | (0.46 | )
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit): |  |  |  |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | 235,370,384 |  |  | $ | (1,234,680 | ) |  | $ | 234,135,704 |
Non-controlling interest |  | $ | (1,765,058 | ) |  | $ | 376,962 |  |  | $ | (1,388,096 | )
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
Condensed Consolidated Statement of Cash Flows: |  |  |  |  |  |  |  |  |  |  |  |
Net loss |  | $ | (18,963,189 | ) |  | $ | 2,729,875 |  |  | $ | (16,233,314 | )
Accounts receivable |  | $ | (722,251 | ) |  | $ | (4,450,283 | ) |  | $ | (5,222,534 | )
Other current assets |  | $ | (1,303,495 | ) |  | $ | (1,000,000 | ) |  | $ | (2,303,495 | )
Deferred revenue |  | $ | 7,561,943 |  |  | $ | 3,312,487 |  |  | $ | 10,874,430 |
Accrued expenses |  | $ | 7,704,036 |  |  | $ | (97,031 | ) |  | $ | 7,607,005 |
Net cash provided by operating activities |  | $ | 15,944,841 |  |  | $ | 495,048 |  |  | $ | 16,439,889 |
Distributions to non-controlling interest |  | $ | (108,000 | ) |  | $ | (495,048 | ) |  | $ | (603,048 | )
Net cash used in financing activities |  | $ | (2,688,722 | ) |  | $ | (495,048 | ) |  | $ | (3,183,770 | )
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
|  | As of and for the Three Months Ended March 31, 2025 |
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
Condensed Consolidated Statement of Operations: |  |  |  |  |  |  |  |  |
Telehealth revenue, net |  | $ | 52,456,481 |  |  | $ | (1,568,582 | ) |  | $ | 50,887,899 |
Total revenues, net |  | $ | 65,697,756 |  |  | $ | (1,568,582 | ) |  | $ | 64,129,174 |
Gross profit |  | $ | 57,054,040 |  |  | $ | (1,568,582 | ) |  | $ | 55,485,458 |
Operating income |  | $ | 2,542,924 |  |  | $ | (1,568,582 | ) |  | $ | 974,342 |
Net income |  | $ | 1,916,649 |  |  | $ | (1,568,582 | ) |  | $ | 348,067 |
Net income (loss) attributable to LifeMD, Inc. |  | $ | 1,384,804 |  |  | $ | (1,568,582 | ) |  | $ | (183,778 | )
Net income (loss) attributable to LifeMD, Inc. common stockholders |  | $ | 608,241 |  |  | $ | (1,568,582 | ) |  | $ | (960,341 | )
Basic earnings (loss) per share attributable to LifeMD, Inc. common stockholders |  | $ | 0.01 |  |  | $ | (0.03 | ) |  | $ | (0.02 | )
Diluted earnings (loss) per share attributable to LifeMD, Inc. common stockholders |  | $ | 0.01 |  |  | $ | (0.03 | ) |  | $ | (0.02 | )
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit): |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | 235,644,977 |  |  | $ | 5,166,295 |  |  | $ | 240,811,272 |
Non-controlling interest |  | $ | (1,935,978 | ) |  | $ | (88,961 | ) |  | $ | (2,024,939 | )
Condensed Consolidated Statement of Cash Flows: |  |  |  |  |  |  |  |  |  |  |  |
Net income |  | $ | 1,916,649 |  |  | $ | (1,568,582 | ) |  | $ | 348,067 |
Accounts receivable |  |  | (1,974,961 | ) |  |  | 1,507,106 |  |  |  | (467,855 | )
Deferred revenue |  |  | 144,985 |  |  |  | 61,475 |  |  |  | 206,460 |
Net cash provided by operating activities |  | $ | 3,068,387 |  |  | $ | - |  |  | $ | 3,068,387 |
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
|  | For the Three Months Ended June 30, 2025 |
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
Condensed Consolidated Statement of Operations: |  |  |  |  |  |  |  |  |
Telehealth revenue, net |  | $ | 48,563,672 |  |  | $ | 455,210 |  |  | $ | 49,018,882 |
Total revenues, net |  | $ | 62,218,185 |  |  | $ | 455,210 |  |  | $ | 62,673,395 |
Gross profit |  | $ | 54,787,281 |  |  | $ | 455,210 |  |  | $ | 55,242,491 |
Operating loss |  | $ | (906,772 | ) |  | $ | 455,210 |  |  | $ | (451,562 | )
Net loss |  | $ | (1,569,799 | ) |  | $ | 455,210 |  |  | $ | (1,114,589 | )
Net loss attributable to LifeMD, Inc. |  | $ | (2,074,874 | ) |  | $ | 455,210 |  |  | $ | (1,619,664 | )
Net loss attributable to LifeMD, Inc. common stockholders |  | $ | (2,851,436 | ) |  | $ | 455,210 |  |  | $ | (2,396,226 | )
Basic loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.06 | ) |  | $ | 0.01 |  |  | $ | (0.05 | )
Diluted loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.06 | ) |  | $ | 0.01 |  |  | $ | (0.05 | )
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
|  | As of and for the Six Months Ended June 30, 2025 |
|  | As Previously Reported |  |  | Adjustment |  |  | As Revised |
Condensed Consolidated Statement of Operations: |  |  |  |  |  |  |  |  |
Telehealth revenue, net |  | $ | 101,020,153 |  |  | $ | (1,113,372 | ) |  | $ | 99,906,781 |
Total revenues, net |  | $ | 127,915,941 |  |  | $ | (1,113,372 | ) |  | $ | 126,802,569 |
Gross profit |  | $ | 111,841,321 |  |  | $ | (1,113,372 | ) |  | $ | 110,727,949 |
Operating income |  | $ | 1,636,152 |  |  | $ | (1,113,372 | ) |  | $ | 522,780 |
Operating income (loss) |  |  | 1,636,152 |  |  |  | (1,113,372 | ) |  |  | 522,780 |
Net income (loss) |  | $ | 346,850 |  |  | $ | (1,113,372 | ) |  | $ | (766,522 | )
Net loss attributable to LifeMD, Inc. |  | $ | (690,070 | ) |  | $ | (1,113,372 | ) |  | $ | (1,803,442 | )
Net loss attributable to LifeMD, Inc. common stockholders |  | $ | (2,243,195 | ) |  | $ | (1,113,372 | ) |  | $ | (3,356,567 | )
Basic loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.05 | ) |  | $ | (0.03 | ) |  | $ | (0.08 | )
Diluted loss per share attributable to LifeMD, Inc. common stockholders |  | $ | (0.05 | ) |  | $ | (0.03 | ) |  | $ | (0.08 | )
Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit): |  |  |  |  |  |  |  |  |
Accumulated deficit |  | $ | 238,496,413 |  |  | $ | 4,711,085 |  |  | $ | 243,207,498 |
Non-controlling interest |  | $ | (2,164,934 | ) |  | $ | (88,961 | ) |  | $ | (2,253,895 | )
Condensed Consolidated Statement of Cash Flows: |  |  |  |  |  |  |  |  |  |  |  |
Net income (loss) |  | $ | 346,850 |  |  | $ | (1,113,372 | ) |  | $ | (766,522 | )
Accounts receivable |  | $ | 887,684 |  |  | $ | 645,683 |  |  | $ | 1,533,367 |
Deferred revenue |  | $ | (2,690,893 | ) |  | $ | (32,312 | ) |  | $ | (2,723,205 | )
Accrued expenses |  | $ | (5,865,264 | ) |  | $ | 500,000 |  |  | $ | (5,365,264 | )
Net cash provided by operating activities |  | $ | 11,707,834 |  |  | $ | - |  |  | $ | 11,707,834 |

X
- References No definition available. + Details
Name: | us-gaap_AccountingChangesAndErrorCorrectionsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 250 -SubTopic 10 -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9 + Details
Name: | us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration